Itraconazole with ablation to prevent esophageal cancer in Barrett's esophagus
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests if adding the antifungal drug itraconazole to standard ablation therapy can help prevent esophageal cancer in people with high-risk Barrett's esophagus. You must have a confirmed diagnosis of Barrett's esophagus with low- or high-grade dysplasia or early-stage cancer, and be planning to have ablation treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have Barrett's esophagus (at least 2 cm long) with low- or high-grade dysplasia or stage T1a esophageal cancer, and have not had previous treatment
- You are 18 years or older
- Your blood counts, liver, and kidney function are within safe limits (tests will be done to check)
- You do not have serious heart problems, such as heart failure or a long QT interval on an EKG
- You are not pregnant, breastfeeding, or planning to become pregnant; you must use effective non-estrogen birth control during and 2 months after the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial tests whether obeticholic acid (a medicine) can help stop Barrett’s esophagus from getting worse. You must already be taking acid-suppressing medicine and have non-cancer Barrett’s changes, and the study checks safety and whether the lining improves or stays stable.
This trial tests whether adding the antifungal drug itraconazole to the usual chemotherapy and radiation before surgery can improve the chance of no cancer cells remaining at surgery. It is for patients with esophageal or gastroesophageal junction cancer that can be surgically removed.
This study looks at how radiofrequency ablation (RFA) affects the flexibility and lining of the esophagus in people with Barrett's esophagus and early cancer. It may help doctors understand how this treatment works.
This study looks at people with Barrett's esophagus who are about to have a procedure to remove a suspicious spot. It tests a new way to predict if cancer might come back, and it checks how learning your risk affects your worry and quality of life.
This study compares two approaches for people with Barrett's esophagus and low-grade dysplasia: regular surveillance (monitoring with endoscopies) versus endoscopic treatment to remove the abnormal cells. It aims to see which approach is better at preventing progression to more serious conditions.
This study tests less invasive ways to detect high-grade dysplasia (very abnormal cells) and esophageal cancer in people with Barrett's esophagus, a condition that can increase cancer risk. It looks for these changes using cell samples taken during a routine endoscopy, which may be quicker and more comfortable than standard biopsies.
Hear when a new Barrett Esophagus trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.